Tokyo Metropolitan Bokutoh Hospital is located in Kotobashi, Sumida, Tokyo, Japan. It has 765 beds and is run by the Tokyo Metropolitan Government.

There are 765 beds in Tokyo Metropolitan Bokutoh Hospital.

During the past decade, Tokyo Metropolitan Bokutoh Hospital conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 3 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 3 clinical trials were completed. i.e. 42.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tokyo Metropolitan Bokutoh Hospital" #1 sponsor was "Janssen Research & Development, LLC" with 3 trials, followed by "Bayer" with 2 trials sponsored, "Ferring Pharmaceuticals" with 2 trials sponsored, "Gilead Sciences" with 2 trials sponsored and "Haruhiko Fukuda" with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tokyo Metropolitan Bokutoh Hospital" #1 collaborator was "Ministry of Health, Labour and Welfare, Japan" with 2 trials as a collaborator, "Regeneron Pharmaceuticals" with 2 trials as a collaborator, "Australian and New Zealand Intensive Care Research Centre" with 1 trials as a collaborator, "Berry Consultants" with 1 trials as a collaborator and "Boehringer Ingelheim" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Tokyo Metropolitan Bokutoh Hospital" are "COVID-19" (2 trials), "Cervical Ripening" (2 trials), "Gastric Neoplasm" (2 trials), "Retinopathy of Prematurity (ROP)" (2 trials) and "Acute Heart Failure" (1 trials). Many other conditions were trialed in "Tokyo Metropolitan Bokutoh Hospital" in a lesser frequency.

Most popular intervention types in "Tokyo Metropolitan Bokutoh Hospital" are "Drug" (13 trials), "Procedure" (5 trials), "Other" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Dinoprostone" (2 trials), "Eylea (Aflibercept, BAY86-5321)" (2 trials), "Guselkumab" (2 trials) and "Laser photocoagulation" (2 trials). Other intervention names were less common.

The vast majority of trials in "Tokyo Metropolitan Bokutoh Hospital" are 12 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Tokyo Metropolitan Bokutoh Hospital". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Tokyo Metropolitan Bokutoh Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Tokyo Metropolitan Bokutoh Hospital, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".